Screener
Integra LifeSciences IART Ratios & Valuation
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 52.5%-0.1pp | 51.9%-1.6pp | 50.9%-3.9pp | 52.3%-2.6pp | 52.6%-3.4pp | |
| Operating margin | 2.6%+33.5pp | -29.8%-30.3pp | -31.6%-33.3pp | -29.3%-31.1pp | -30.9%-34.9pp | |
| Net margin | -0.4%— | -30.1%— | -31.6%— | —— | —— | |
| Returns | ||||||
| Return on equity | -0.7%— | -38.6%— | -39.9%— | —— | —— | |
| Return on invested capital | 1.5%+20.0pp | -16.4%-16.7pp | -17.6%-18.7pp | -16.1%-17.2pp | -18.5%-20.7pp | |
| Efficiency | ||||||
| Asset turnover | 0.5×0.0× | 0.4×0.0× | 0.4×0.0× | 0.4×0.0× | 0.4×0.0× | |
| Liquidity | ||||||
| Current ratio | 3.6×+2.4× | 3.4×+2.2× | 2.5×+1.4× | 3.1×+1.9× | 1.2×-2.2× | |
| Leverage | ||||||
| Debt-to-equity | 1.9×+0.1× | 1.9×+0.6× | 1.8×+0.6× | 1.9×+0.6× | 1.8×+0.9× | |
| Net debt / EBITDA | 8.3×— | —— | —— | —— | —— | |
| Per Share | ||||||
| Book value per share | $13.35-1.4% | $13.55-32.0% | $13.61-32.2% | $13.52-32.1% | $13.54-31.7% | |
| Valuation | ||||||
| Market capitalization | $1.33B+38.0% | $734.17M-56.8% | $967.42M-44.7% | $1.12B-20.6% | $922.44M-59.3% | |
| Price / sales | 0.8×+0.2× | 0.4×-0.6× | 0.6×-0.5× | 0.7×-0.2× | 0.6×-0.9× | |
| Price / book | 1.3×+0.3× | 0.7×-0.4× | 0.9×-0.2× | 1.1×+0.2× | 0.9×-0.6× | |
| EV / EBITDA | 14.6×— | —— | —— | —— | —— |
FAQ
- What are Integra LifeSciences's profit margins?
- Integra LifeSciences (IART) runs a 52.5% gross margin and a 2.6% operating margin, with a -0.4% net margin.
- Where do Integra LifeSciences's ratios come from?
- Every ratio is computed from Integra LifeSciences's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
